tirzepatide vs semaglutide moa 10 and 15 mg versus 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison - Hankosky - 2025 - Diabetes, Obesity and Metabolism From single to triple agonists

Nootropic peptides do something fundamentally different: they drive structural changes in the brain, including neurogenesis, synaptogenesis, and neurotrophic factor elevation

Real-world experiences highlight the strengths and limitations of each approach

Above all, the experience continues to reward attention and restraint: stay observant, pace your choices, and you can convert small edges into sustainable outcomes across many sessions without letting variance dictate your entire narrative.

There have been anecdotal reports that GLP-1 medications may contribute to anorexia by blunting hunger cues for people whove developed an unhealthy aversion to food